Skip to content

Design Therapeutics, Inc. DSGN Short- term Investments

Short- term Investments at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
Vor Biopharma logo
Vor BiopharmaVOR
GeneDx Holdings logo
GeneDx HoldingsWGS
Tango Therapeutics logo
Tango TherapeuticsTNGX
PTC Therapeutics logo
PTC TherapeuticsPTCT

Other financials

Income statement

See full
Revenue-
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation

See full
Market cap$839.42M+295%
Enterprise value$829.39M+313%

Profitability

See full
Operating margin-3,685.8%
Net margin-3,663.7%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0.0×
Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Design Therapeutics, Inc.'s short- term investments?
Design Therapeutics, Inc. (DSGN) reported short- term investments of $210.05M in Q1 2026.
How has Design Therapeutics, Inc.'s short- term investments changed year-over-year?
Design Therapeutics, Inc.'s short- term investments decreased by 2.8% year-over-year, from $216.01M to $210.05M.
What is the long-term trend for Design Therapeutics, Inc.'s short- term investments?
Over 5 years (2020 to 2025), Design Therapeutics, Inc.'s short- term investments has grown at a 43.2% compound annual growth rate (CAGR), from $33.71M to $202.99M.